Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A. is dated April 13, 2026. The report serves as a notification of a press release issued on the same date (Exhibit 99.1). The registrant is a foreign private issuer filing under Form 20-F.
Key Financial Metrics
The provided filing text contains only the cover page and exhibit index. It does not include the content of the press release or any financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity is not available in this document.
Material Changes
No material changes versus prior periods can be identified as the filing text does not contain comparative financial data or operational updates.
Guidance, Outlook, and Risks
The filing references a press release but does not include its text. Therefore, no guidance, management commentary, risk factors, contingencies, or unusual items are disclosed in the provided content.
Investor Verification Checklist
- Verify the full content of the press release dated April 13, 2026, referenced as Exhibit 99.1.
- Confirm the specific clinical, commercial, or corporate event triggering this filing.
- Review the company's most recent Form 20-F for baseline financial data to contextualize the new announcement.